Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 20/20 | 0.58 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18643569 | 0.81 | LOX (0.59) | LOXLOXL2MAOA | |
| SCHEMBL3131218 | 0.79 | LOX (0.86) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL1838092 | 0.79 | LOX (0.58) | LOXLOXL2KCNH2AOC3LOXL3 | |
| Hydrochloric Acid SCHEMBL15486681 | 0.78 | LOX (0.83) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL19436416 | 0.77 | LOX (0.57) | LOXLOXL2 | |
| SCHEMBL13425238 | 0.76 | LOX (0.54) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL4090626 | 0.76 | LOX (0.54) | LOXLOXL2 | |
| SCHEMBL4090624 | 0.73 | LOX (0.56) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL19260026 | 0.73 | LOX (0.70) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL6638304 | 0.73 | LOX (0.56) | LOXLOXL2KCNH2AOC3LOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104592211-B | Biphenyl compound and application thereof | 广东东阳光药业有限公司 | 2018-10-16 | — | — | CN | disclosed |
| CN-104592211-A | Biphenyl compound and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-05-06 | — | — | CN | disclosed |
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | CCNA1, CCNB1, CCNT1 | LOX 3821/4885LOXL2 3126/4885KCNH2 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.